Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age

Carlos E. Vigil, Wei Tan, George Deeb, Sheila N. Sait, Annemarie W. Block, Petr Starostik, Elizabeth A. Griffiths, James E. Thompson, Jessica D. Greene, Laurie A. Ford, Eunice S. Wang, Meir Wetzler*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

We designed a phase II study evaluating the upfront combination of clofarabine and daunorubicin in acute myeloid leukemia (AML) patients ≥ 60 years old. The median age of the 21 patients was 69 (range 60-85) years. Fourteen patients (67%) had unfavorable risk features. The principal toxicities were grade ≥3 infections and prolonged myelosuppression. Three (14%) deaths occurred from infectious complications. Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months.

Original languageEnglish (US)
Pages (from-to)1468-1471
Number of pages4
JournalLeukemia Research
Volume37
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Keywords

  • AML
  • Clinical trial
  • Clofarabine
  • Daunorubicin
  • Elderly

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age'. Together they form a unique fingerprint.

Cite this